Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
22/12/202308:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/12/202308:05GlobeNewswire Inc.Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/12/202308:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/12/202308:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/12/202308:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/12/202308:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/12/202308:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202308:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202308:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/12/202303:41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/12/202308:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/12/202308:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/12/202323:30GlobeNewswire Inc.Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive YearNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/12/202311:30GlobeNewswire Inc.Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported OutcomesNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/12/202304:30GlobeNewswire Inc.Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term OutcomesNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/12/202323:00GlobeNewswire Inc.Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/12/202318:30GlobeNewswire Inc.Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IONASDAQ:REGNRegeneron Pharmaceuticals Inc
07/12/202308:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/12/202308:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/12/202308:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/12/202308:05GlobeNewswire Inc.Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology PortfolioNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/11/202317:30GlobeNewswire Inc.Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNASDAQ:REGNRegeneron Pharmaceuticals Inc
17/11/202303:39Dow Jones NewsRegeneron Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since May 2018 -- Data TalkNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/11/202308:05GlobeNewswire Inc.Regeneron Announces Investor Conference PresentationNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN